Hospital Teresa Herrera C.H.U.A.C.

At Hospital Teresa Herrera C.H.U.A.C., clinical research in Oncology focuses on cancers such as advanced ALK-positive non-small cell lung cancer, HER2-positive early-stage breast cancer, and broader solid tumors. These studies are designed to compare new treatment approaches with existing care, while also looking at how well patients respond over time and how treatment affects overall wellbeing.

• Evaluating a new targeted therapy approach for advanced ALK-positive non-small cell lung cancer
• Studying treatment strategies for HER2-positive early-stage breast cancer and recurrence prevention
• Monitoring safety and tolerability in research on solid tumors

This work reflects a strong focus on improving cancer control, with attention to both effectiveness and patient-centered outcomes in the Oncology Department.

The site also supports research in Immune System Diseases, especially allergic rhinoconjunctivitis linked to Dermatophagoides pteronyssinus and Dermatophagoides farinae. These trials aim to assess whether allergen-based treatment can improve symptoms and quality of life for people with persistent allergies, including those with controlled asthma.

• Testing the clinical benefit of allergen immunotherapy for allergic rhinoconjunctivitis
• Assessing symptom improvement in patients with dust mite-related allergic disease
• Comparing active treatment with placebo to better understand effectiveness

Research in this area at Hospital Teresa Herrera C.H.U.A.C. is centered on reducing allergy burden and improving day-to-day respiratory and nasal health.

Another part of the research portfolio explores targeted cancer treatment combinations for patients with neoplasms. These studies are aimed at understanding whether specific drug combinations can help control disease more effectively in people with solid tumors, while continuing to track safety and overall treatment impact.

• Assessing new combination approaches for solid tumor management
• Investigating whether treatment can better control cancer growth and progression
• Observing safety and tolerability alongside clinical benefit

This research adds to the site’s broader efforts in oncology by examining how targeted therapies may improve outcomes for patients with difficult-to-treat cancers.

With 4 clinical trials and 7 investigators, the site maintains a focused but diverse research program spanning Oncology and Immune System Diseases. The studies combine treatment evaluation, symptom control, and outcome improvement across cancer and allergy-related conditions.

• Testing new therapies and treatment combinations in cancer care
• Evaluating effectiveness in HER2-positive breast cancer and ALK-positive lung cancer
• Advancing care for allergic rhinoconjunctivitis through targeted immune-based treatment

The clinical trial landscape at Hospital Teresa Herrera C.H.U.A.C. shows a clear commitment to improving care for patients with both malignant and immune-mediated diseases.